Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab, Atezolizumab, and FSRT in Recurrent Glioblastoma
NCT04729959Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2022
- Primary completion
- Jun 2025
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab, atezolizumab in glioblastoma (GBM), sponsored by National Cancer Institute. Started Mar 2022; status: active, not recruiting.
02
Drugs
tocilizumabatezolizumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04729959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04729959.